Pfizer
Ticker > Company >

Pfizer share price

Pfizer Ltd.

NSE: PFIZER BSE: 500680 SECTOR: Pharmaceuticals & Drugs  1.57 L   447   55

5173.30
-30.30 (-0.58%)
BSE: 18 Sep 04:01 PM

Price Summary

Today's High

₹ 5311.9

Today's Low

₹ 5136

52 Week High

₹ 6039

52 Week Low

₹ 3742.9

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationFair
The stock’s market price justifies its intrinsic value.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsAverage
The company could improve upon its asset employment.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

₹ 23666.67 Cr.

Enterprise Value

₹ 20868.19 Cr.

No. of Shares

4.57 Cr.

P/E

29.27

P/B

5.37

Face Value

₹ 10

Div. Yield

3.19 %

Book Value (TTM)

₹  963.8

CASH

₹ 2800.98 Cr.

DEBT

₹ 2.5 Cr.

Promoter Holding

63.92 %

EPS (TTM)

₹  176.76

Sales Growth

4.02%

ROE

19.65 %

ROCE

26.21%

Profit Growth

39.23 %

Add Your Ratio

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Pfizer Ltd.

Becosules Folvite VIAGRA COREX LS RABEPRAZOLE GELUSIL BRONCOVIT WYSOLONE ANACIN Zavicefta Zinforo Meronem Magnex Zosyn

Index Presence

The company is present in 20Indices.

NYMIDSML400MQ100

Nifty MidSmallcap400 Momentum Quality 100 Index
49617.25
  39.8499999999985 (0.0803793664048591%)

NFTSML250MOMQ100

Nifty Smallcap250 Momentum Quality 100 index
46841.35
  -9.65000000000146 (-0.0205972124394438%)

NFTMIDSMLHEALTH

Nifty MidSmall Healthcare
45241.9
  494.75 (1.10565700832344%)

NFTSMLCAP250Q50

Nifty Smallcap250 Quality 50
27473.75
  34.2000000000007 (0.124637612497303%)

NIFTY500

Nifty 500
23518.9
  73.7000000000007 (0.314350058860668%)

NIFTYMIDSMALL400

Nifty MidSmallcap 400
20322.2
  45.0499999999993 (0.222171261740423%)

NIF500LGMIDSML

Nifty500 LargeMidSmall Equal-Cap Weighted Index
18117.95
  43.7000000000007 (0.241780433489636%)

NIFTYSMALLCAP250

Nifty Smallcap 250
17481.65
  10.9000000000015 (0.0623899947054474%)

NY500MUL50:25:25

Nifty500 Multicap 50:25:25
16410.7
  44.0500000000011 (0.269144876929617%)

NFT500EQUAL

Nifty 500 Equal Weight
14656.25
  17.25 (0.117835917753939%)

NIFTYTOTALMCAP

Nifty Total Market index
13237.7
  38.7000000000007 (0.293204030608374%)

NIFTYFULLMIDCAP100

NIFTY FULL MIDCAP 100
5987.56
  -42.7999999999993 (-0.709742038617911%)

SMLCAP

S&P Bse Small Cap
54532.75
  -4.27999999999884 (-0.00784787877153859%)

BSE HC

S&P Bse Healthcare
45130.04
  391.309999999998 (0.874656030691967%)

BSE500

S&P Bse 500
36930.41
  117.280000000006 (0.318581984199673%)

S&P MIDSMLCAP

S&P Bse MidSmallCap
12414.1
  73.2299999999996 (0.593394144821224%)

MSL400

S&P Bse 400 MidSmallCap
12313.95
  22.3500000000004 (0.181831494679296%)

BSE1000

Bse 1000
11004.98
  32.75 (0.298480801076906%)

ALLCAP

S&P Bse Allcap
10130.99
  38.3799999999992 (0.380278243189802%)

SML250

S&P Bse 250 SmallCap
6987.85
  -0.6899999999996 (-0.00987330687095556%)

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.

PE Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

PB Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year4.02%
3 Year-4.4%
5 Year1.18%

Profit Growth

1 Year39.23%
3 Year7.81%
5 Year8.56%

ROE%

1 Year19.65%
3 Year18.8%
5 Year19.38%

ROCE %

1 Year26.21%
3 Year25.38%
5 Year25.91%

Debt/Equity

0.0006

Price to Cash Flow

35.87

Interest Cover Ratio

120.54

CFO/PAT (5 Yr. Avg.)

0.77519054840601

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2025 63.92 0.00
Mar 2025 63.92 0.00
Dec 2024 63.92 0.00
Sep 2024 63.92 0.00
Jun 2024 63.92 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • Company has been maintaining healthy ROCE of 25.3821333333333% over the past 3 years.
  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 120.54.
  • The Company has been maintaining an effective average operating margins of 30.5291314044038% in the last 5 years.
  • Company’s PEG ratio is 0.746101585378764.
  • The company has an efficient Cash Conversion Cycle of 21.8583 days.
  • Company has a healthy liquidity position with current ratio of 6.1682.
  • The company has a high promoter holding of 63.92%.

 Limitations

  • The company has shown a poor profit growth of 7.81076076897571% for the Past 3 years.
  • The company has shown a poor revenue growth of -4.3990006351423% for the Past 3 years.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025
Net Sales 562.86 588.59 537.99 591.91 603.05
Total Expenditure 385.37 399.34 392 364.41 393.03
Operating Profit 177.49 189.25 145.99 227.5 210.02
Other Income 41.84 43.07 42.76 44.58 67.17
Interest 2.11 2.1 1.51 2.69 3.25
Depreciation 14.6 14.99 14.8 16.4 14.41
Exceptional Items 0 0 0 172.81 0
Profit Before Tax 202.62 215.23 172.44 425.8 259.53
Tax 51.91 56.88 44.84 94.86 67.78
Profit After Tax 150.71 158.35 127.6 330.94 191.75
Adjusted EPS (Rs) 32.94 34.61 27.89 72.34 41.91

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Net Sales 2238.55 2610.99 2424.76 2193.17 2281.35
Total Expenditure 1526.15 1775.05 1615.81 1557.85 1541.03
Operating Profit 712.4 835.94 808.95 635.32 740.32
Other Income 81.12 62.65 101.05 180.51 172.25
Interest 15.39 10.7 13.48 15.43 8.5
Depreciation 109.41 115 105.51 62.28 60.79
Exceptional Items 0 0 33 7.95 172.81
Profit Before Tax 668.72 772.89 824.01 746.07 1016.09
Tax 171.11 160.33 200.08 194.74 248.49
Net Profit 497.61 612.56 623.93 551.33 767.6
Adjusted EPS (Rs.) 108.77 133.89 136.38 120.51 167.78

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity and Liabilities
Share Capital 45.75 45.75 45.75 45.75 45.75
Total Reserves 2347.29 2818.66 3161.55 3549.79 4171.66
Borrowings 0 0 0 0 0
Other N/C liabilities 85.06 136.23 38.41 32.74 54.89
Current liabilities 774.34 852.89 657.35 546.56 569.51
Total Liabilities 3252.44 3853.53 3903.06 4174.84 4841.81
Assets
Net Block 864.74 840.96 749.25 712.71 723.62
Capital WIP 2.76 1.15 7.93 0.4 7.64
Intangible WIP 0 0 0 0 0
Investments 0 0 0 0 0
Loans & Advances 291.62 549.2 550.26 589.78 541.34
Other N/C Assets 220.02 100.78 102.28 134.14 56.36
Current Assets 1873.3 2361.44 2493.34 2737.81 3512.85
Total Assets 3252.44 3853.53 3903.06 4174.84 4841.81
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Profit from operations 668.72 772.89 824.01 746.07 1016.09
Adjustment 54.53 76.17 -131.26 -89.32 -256.91
Changes in Assets & Liabilities -91.78 43.94 -34.49 -246.09 56.79
Tax Paid -204.14 -225.92 -302.58 -153.82 -156.22
Operating Cash Flow 427.33 667.08 355.68 256.84 659.75
Investing Cash Flow -468.84 -575.02 -36.05 53.7 -71.34
Financing Cash Flow -1571.07 -180.51 -345.79 -235.14 -205.34
Net Cash Flow -1612.58 -88.45 -26.16 75.4 383.07

Corporate Actions

Investors Details

PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
promoters 63.92 63.92 63.92 63.92 63.92
john wyeth & brother ltd 1.93 1.93 1.93 1.93 1.93
parke, davis & company ll... 2.09 2.09 2.09 2.09 2.09
pfizer east india b v 39.75 39.75 39.75 39.75 39.75
pharmacia corporation 1.71 1.71 1.71 1.71 1.71
warner-lambert company ll... 2.60 2.60 2.60 2.60 2.60
wyeth holdings corporatio... 3.56 - 3.56 3.56 3.56
wyeth llc 12.28 12.28 12.28 12.28 12.28
wyeth holdings corporatio... - 3.56 - - -
PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
investors 36.08 36.08 36.08 36.08 36.08
0 - - - - 2.33
atul limited 2.10 2.10 2.10 2.10 2.10
icici prudential mutual f... - - - 1.13 1.08
investor education and pr... 0.88 - 0.93 - 0.92
life insurance corporatio... 5.79 4.31 4.07 3.93 3.88
nippon life india trustee... - - - 4.17 4.17
sbi mutual fund - - - 1.13 1.13
investor education and pr... - 0.88 - 0.92 -
quant mutual fund - - - 2.33 -
icici prudential mnc fund... - - 1.10 - -
nippon life india trustee... - - 3.76 - -
quant mutual fund - quant... - - 2.35 - -
sbi nifty smallcap 250 in... - - 1.52 - -
nippon life india trustee... 3.73 3.76 - - -
quant mutual fund - quant... - 2.08 - - -
sbi magnum midcap fund - 1.31 - - -

Annual Reports

Title Link
Title Link
Annual Report 2025
Annual Report 2024
Annual Report 2023
Annual Report 2022
Annual Report 2021
Annual Report 2020
Annual Report 2019
Annual Report 2018
Annual Report 2017
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
 No Credit reports exist for this company.Report us
TYPE AGENCY Link
TYPE AGENCY Link
Research ICICI Securities Limited
Research Nirmal Bang Institutional

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
Concall Q1FY21
Concall Q4FY19
TYPE QUARTER Link
TYPE QUARTER Link
Presentation Q4FY19

Company News

Pfizer signs MoU with DPIIT 5 Sep, 5:21 PM Pfizer - Quaterly Results 13 Aug, 4:58 PM Pfizer - Quaterly Results 13 Aug, 4:58 PM Pfizer - Quaterly Results 13 Aug, 4:58 PM Pfizer launches 20-valent Pneumococcal Conjugate Vaccine for adults in India 12 Aug, 9:51 AM Pfizer - Quaterly Results 19 May, 10:27 PM Pfizer - Quaterly Results 19 May, 10:27 PM Pfizer informs about disclosures 19 Mar, 3:02 PM Pfizer gets nod to enter into Marketing and Supply Agreement with Mylan Pharmaceuticals 21 Feb, 3:44 PM Pfizer informs about disclosure 4 Feb, 11:56 AM Pfizer - Quaterly Results 31 Jan, 5:04 PM Pfizer - Quaterly Results 31 Jan, 5:04 PM Pfizer - Quaterly Results 31 Jan, 5:04 PM Pfizer informs about issuance of duplicate share certificates 11 Dec, 4:47 PM Pfizer - Quaterly Results 28 Oct, 6:05 PM Pfizer - Quaterly Results 28 Oct, 6:05 PM Pfizer - Quaterly Results 28 Oct, 6:05 PM Pfizer informs about newspaper publication 8 Aug, 4:58 PM Pfizer - Quaterly Results 29 Jul, 7:47 PM Pfizer - Quaterly Results 29 Jul, 7:47 PM Pfizer informs about annual secretarial compliance report 27 May, 4:31 PM Pfizer - Quaterly Results 17 May, 7:41 PM Pfizer - Quaterly Results 17 May, 7:41 PM Pfizer - Quaterly Results 9 Feb, 2:40 PM Pfizer - Quaterly Results 9 Feb, 2:40 PM Pfizer - Quaterly Results 9 Feb, 2:40 PM Pfizer informs about appointment of executive director 22 Jan, 9:41 AM Pfizer - Quaterly Results 28 Oct, 3:26 PM Pfizer - Quaterly Results 28 Oct, 3:26 PM Pfizer - Quaterly Results 28 Oct, 3:26 PM Pfizer informs about change in management 18 Aug, 4:44 PM Pfizer - Quaterly Results 11 Aug, 4:29 PM Pfizer - Quaterly Results 11 Aug, 4:29 PM Pfizer - Quaterly Results 11 Aug, 4:29 PM Pfizer informs about loss of share certificates 20 Jul, 4:56 PM Pfizer informs about loss of share certificates 20 Jun, 11:15 AM Pfizer reports marginal rise in Q4 net profit 16 May, 10:09 AM Pfizer - Quaterly Results 15 May, 5:53 PM Pfizer - Quaterly Results 15 May, 5:53 PM Pfizer informs about loss of share certificate 20 Apr, 5:03 PM Pfizer informs about issue of duplicate certificate 28 Mar, 2:46 PM Pfizer to acquire Seagen for $43 billion 14 Mar, 2:07 PM Pfizer transfers Thane business undertaking to Vidhi Research and Development 27 Feb, 10:29 AM Pfizer informs about outcome of board meeting 9 Feb, 5:21 PM Pfizer - Quaterly Results 9 Feb, 4:42 PM Pfizer - Quaterly Results 9 Feb, 4:42 PM Pfizer - Quaterly Results 9 Feb, 4:42 PM Pfizer - Quaterly Results 11 Nov, 4:15 PM Pfizer - Quaterly Results 11 Nov, 4:15 PM Pfizer - Quaterly Results 11 Nov, 4:15 PM

Pfizer Stock Price Analysis and Quick Research Report. Is Pfizer an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Pfizer. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Pfizer has a PE ratio of 29.3758737094841 which is high and comparatively overvalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Pfizer has ROA of 17.0263% which is a good sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Pfizer has a Current ratio of 6.1682.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Pfizer has a ROE of 19.6494%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Pfizer has a Debt to Equity ratio of 0.0006 which means that the company has low proportion of debt in its capital.

  • Sales growth: Pfizer has reported revenue growth of 4.0207% which is poor in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Pfizer for the current financial year is 32.450961053762%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Pfizer is Rs 165 and the yield is 3.184%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Pfizer is Rs 176.7607. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Pfizer in Ticker for free. Also, one can get the intrinsic value of Pfizer by using Valuation Calculators, which are available with a Finology ONE subscription. 

Pfizer FAQs

Q1. What is Pfizer share price today?
Ans: The current share price of Pfizer is Rs 5192.5.

Q2. What is the market capitalisation of Pfizer?
Ans: Pfizer has a market capitalisation of Rs 23754.509841 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Pfizer?
Ans: The PE ratio of Pfizer is 29.3758737094841 and the P/B ratio of Pfizer is 5.38753915368789, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Pfizer share?
Ans: The 52-week high share price of Pfizer is Rs 6020, and the 52-week low share price of Pfizer is Rs 3701.

Q5. Does Pfizer pay dividends?
Ans: Currently, Pfizer pays dividends. Dividend yield of Pfizer is around 3.184%.

Q6. What are the face value and book value of Pfizer shares?
Ans: The face value of Pfizer shares is Rs 10, while the book value per share of Pfizer is around Rs 963.7981. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Pfizer?
Ans: Pfizer has a total debt of Rs 2.5 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Pfizer?
Ans: The ROE of Pfizer is 19.6494% and ROCE of Pfizer is 26.2112%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Pfizer a good buy for the long term?
Ans: The Pfizer long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Pfizer undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Pfizer appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Pfizer’s financials?
Ans: You can review Pfizer’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Pfizer

Pfizer Ltd Financials: Check Share Price, Balance Sheet, Annual Report and Quarterly Results for Company Analysis

 

Pfizer Ltd. is a leading pharmaceutical company that has been operating in India for more than fifty years. The company is renowned for its high-quality products, innovative research, and reliable customer service.  We will focus on the various parameters that long-term stock investors should consider while analyzing the company's stock.

Pfizer Ltd  Share Price

The share price of Pfizer Ltd. is a critical parameter that investors should constantly monitor while analyzing the stock. Pfizer Ltd. is listed on the National Stock Exchange (NSE) and the Bombay Stock Exchange (BSE). Investors can regularly track the share price of the company through our trading platform.

Pfizer Ltd Balance Sheet

The balance sheet of Pfizer Ltd. provides valuable insights into the company's financial health and overall stability. For long-term investors considering investing in the company's stock, analyzing the balance sheet is pivotal. At Ticker, investors can refer to the company's balance sheets and utilize our pre-built screening tools to calculate fair value using DCF Analysis, BVPS Analysis, Earnings Multiple Approach, and DuPont Analysis.

Pfizer Ltd  Annual Report

The annual report of Pfizer Ltd. provides detailed information about the company's strategies, performance, and achievements for the preceding year. Long-term investors should carefully study these reports to gain insights into the company's business model, growth trajectory, and future plans. Ticker offers easy access to these annual reports, and they are available as downloadable resources for investors' convenience.

Pfizer Ltd  Dividend

Companies distribute dividends as a return on shareholders' investments. Pfizer Ltd. is a reputable company that values its shareholders and regularly distributes dividends. Investors can explore the company's dividend history and stay updated on the latest dividend announcements through our platform.

Pfizer Ltd  Quarterly Results

Investors should analyze the quarterly results of Pfizer Ltd. to evaluate the company's financial performance over specific periods. Ticker offers comprehensive tools and resources to facilitate this analysis. Investors can access quarterly reports, use analytical tools, and employ pre-built screening tools to assess the company's growth trends, profitability, and overall financial stability.

Pfizer Ltd Stock Price

Monitoring stock prices is essential for investors looking to buy or sell shares of Pfizer Ltd. Ticker platform provides real-time stock price data, ensuring that investors have access to the latest market information to make informed decisions. Investors can closely track the stock's fluctuations, historical trends, and trading volumes to evaluate the stock's performance.

Pfizer Ltd Price Chart

Price charts provide graphical representations of a stock's historical price movements, helping investors identify patterns and trends. Ticker offers comprehensive price charts of Pfizer Ltd.'s stock, enabling investors to visualize the stock's performance over time.

Pfizer Ltd News

Staying up-to-date with the latest news about Pfizer Ltd. is critical for long-term investors. Our platform provides easy access to current news, including market changes, corporate announcements, industry developments, and other relevant events that may impact the stock market. Investors can access these news updates to stay informed and make informed investment decisions.

Pfizer Ltd Concall Transcripts

Conference call transcripts provide valuable insights into Pfizer Ltd.'s management discussions regarding financial results, operational strategies, and future plans. By offering access to concall transcripts, our platform ensures that investors have first-hand information about the company's direction and future prospects.

Pfizer Ltd  Investor Presentations

Pfizer Ltd. presents its corporate strategies, financial performance, and future projections through investor presentations. These presentations offer a glimpse into the company's growth plans, market positioning, and operational strategies. Ticker provides an avenue to download these presentations, enabling investors to make well-informed decisions based on a comprehensive understanding of the company's objectives.

Pfizer Ltd  Promoters

Promoters are individuals or entities responsible for starting the company, raising capital, and maintaining management control. Understanding the vision, strategies, and plans of Pfizer Ltd.'s promoters is integral to evaluating the company's investment potential. Investors can access this information and relevant data about the promoters through our platform.

Pfizer Ltd  Shareholders

Identifying the major shareholders of Pfizer Ltd. along with their respective stakes and voting power is crucial for assessing the company's governance structure and overall stability. Our platform furnishes shareholders' data, offering investors insights into the company's ownership structure.

Pfizer Ltd ROCE

Pfizer Ltd ROCE (Return on Capital Employed) is a critical financial ratio used to assess the company's profitability in relation to the capital it employs. Investors can find the ROCE data in the financials table or ratio section above, gaining insights into how efficiently Pfizer Ltd generates returns on its capital investments. This ratio provides valuable information about the company's capital efficiency and overall profitability, making it an essential metric for stock analysis.

Pfizer Ltd EBITDA

Pfizer Ltd EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is a significant financial measure that reflects the company's operational profitability. By excluding non-operating expenses, the EBITDA data available in the financials table or ratio section above provides insights into Pfizer Ltd's core business performance and operational efficiency.

Pfizer Ltd DPS

Pfizer Ltd DPS (Dividends Per Share) represents the cash distributed to shareholders for each share held in the company. Investors can evaluate Pfizer Ltd's dividend policy and potential returns by referring to the DPS data available in the financials table or ratio section above. This metric is particularly important for those seeking regular income from their investments.

Pfizer Ltd EPS

Pfizer Ltd EPS (Earnings Per Share) is a fundamental metric indicating the company's profitability on a per-share basis. By analyzing the EPS data available in the financials table or ratio section above, investors can assess Pfizer Ltd's earning potential and performance. EPS serves as a significant measure for evaluating the value and growth potential of the company's stock. 

Pfizer's Financial Strength in Balance Sheet

Pfizer's Solid Equity Position

A glance at Pfizer's latest balance sheet highlights a substantial equity base with static share capital maintained at Rs. 45.75 Cr from March 2020 through March 2024. Notably, Pfizer's total reserves have seen a progressive increase, standing at Rs. 3,549.79 Cr in March 2024, indicating a fortified reserve position over the five-year period.

Pfizer's Impressive Liability Management

Pfizer has maintained a debt-free status with zero borrowings, showcasing a strong financial structure reliant on equity. The company's approach to managing its other non-current and current liabilities has been prudent, with a noticeable decrease to Rs. 32.74 Cr and Rs. 546.56 Cr, respectively, by March 2024.

Pfizer's Asset Allocation Strategy

Analyzing the asset side, Pfizer's current assets display a growing curve, rising to Rs. 2,737.81 Cr in March 2024, which suggests grounded liquidity management. Despite a slight contraction in net block assets, the company's overall asset base remains robust at Rs. 4,174.84 Cr in the latest fiscal year.

The presented data offers an analytical perspective on the Standalone Balance Sheet of Pfizer, supplementing stock market enthusiasts with vital information for evaluating market positions, including performance metrics on NSE/BSE indices relevant to Pfizer’s sector.

Read More
X